Natural history of multiple myeloma with de novo del(17p)

被引：45

作者：

Lakshman, Arjun ^{[1
]}

Painuly, Utkarsh ^{[2
,3
]}

Rajkumar, S. Vincent ^{[1
]}

Ketterling, Rhett P. ^{[4
]}

Kapoor, Prashant ^{[1
]}

Greipp, Patricia T. ^{[4
]}

Gertz, Morie A. ^{[1
]}

Buadi, Francis K. ^{[1
]}

Lacy, Martha Q. ^{[1
]}

Dingli, David ^{[1
]}

Dispenzieri, Angela ^{[1
]}

Fonder, Amie L. ^{[1
]}

Hayman, Suzanne R. ^{[1
]}

Hobbs, Miriam A. ^{[1
]}

Gonsalves, Wilson I. ^{[1
]}

Hwa, Yi Lisa ^{[1
]}

Leung, Nelson ^{[1
]}

Go, Ronald S. ^{[1
]}

Lin, Yi ^{[1
]}

Kourelis, Taxiarchis V. ^{[1
]}

Warsame, Rahma ^{[1
]}

Lust, John A. ^{[1
]}

Russell, Stephen J. ^{[1
]}

Zeldenrust, Steven R. ^{[1
]}

Kyle, Robert A. ^{[1
]}

Kumar, Shaji K. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA

[2] Univ Hosp Hradec Kralove, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[3] Charles Univ Prague, Fac Med Hradec Kralove, Hradec Kralove, Czech Republic

[4] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA

来源：

BLOOD CANCER JOURNAL | 2019年 / 9卷 / 3期

关键词：

P53 GENE DELETION; INTERNATIONAL STAGING SYSTEM; MINIMAL RESIDUAL DISEASE; IN-SITU HYBRIDIZATION; PROGNOSTIC-FACTOR; SURVIVAL; IMPACT; ABNORMALITIES; TP53; RISK;

D O I：

10.1038/s41408-019-0191-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We compared the outcomes of 310 patients with newly diagnosed multiple myeloma with del(17p) detected by FISH to patients with high-risk translocations (HRT) (n = 79) and standard-risk (SR) cytogenetics (n = 541). The median progression-free survival (PFS) following initial therapy for the three groups was 21.1, 22, and 30.1 months, respectively (P = 0.437 del(17p) vs. HRT); the median overall survival (OS) was 47.3, 79.1, and 109.8 months, respectively, (P = 0.007del (17p) vs. HRT). PFS and OS for patients with relative loss of 17p (n = 21) were comparable to other patients with del (17p). The PFS was similar between the del(17p) and HRT groups when stratified for age, ISS stage or treatment. The OS of del(17p) and HRT groups were similar in presence of advanced age, ISS III stage or if patients did not receive a proteasome-inhibitor containing induction. ISS III stage, high LDH and HRT, but not the percentage of cells with del (17p) predicted shorter OS in patients with del(17p). The median OS for low (ISS I, normal LDH and no HRT), intermediate (neither low nor high-risk) and high-risk (ISS III and either elevated LDH or coexistent HRT) groups among del(17p) patients were 96.2, 45.4, and 22.8 months, respectively, allowing further risk stratification.

引用

页数：11

共 54 条

[1] The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma [J].

An, Gang ;

Li, Zengjun ;

Tai, Yu-Tzu ;

Acharya, Chirag ;

Li, Qian ;

Qin, Xiaoqi ;

Yi, Shuhua ;

Xu, Yan ;

Feng, Xiaoyan ;

Li, Chengwen ;

Zhao, Jiawei ;

Shi, Lihui ;

Zang, Meirong ;

Deng, Shuhui ;

Sui, Weiwei ;

Hao, Mu ;

Zou, Dehui ;

Zhao, Yaozhong ;

Qi, Junyuan ;

Cheng, Tao ;

Ru, Kun ;

Wang, Jianxiang ;

Anderson, Kenneth C. ;

Qiu, Lugui .

CLINICAL CANCER RESEARCH, 2015, 21 (09) :2148-2156

[2] P53 deletion is not a frequent event in multiple myeloma [J].

Avet-Loiseau, H ;

Li, JY ;

Godon, C ;

Morineau, N ;

Daviet, A ;

Harousseau, JL ;

Facon, T ;

Bataille, R .

BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (03) :717-719

[3] Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome [J].

Avet-Loiseau, Herve ;

Attal, Michel ;

Moreau, Philippe ;

Charbonnel, Catherine ;

Garban, Frederic ;

Hulin, Cyrille ;

Leyvraz, Serge ;

Michallet, Mauricette ;

Yakoub-Agha, Ibrahim ;

Garderet, Laurent ;

Marit, Gerald ;

Michaux, Lucienne ;

Voillat, Laurent ;

Renaud, Marc ;

Grosbois, Bernard ;

Guillerm, Gaelle ;

Benboubker, Lotfi ;

Monconduit, Mathieu ;

Thieblemont, Catherine ;

Casassus, Philippe ;

Caillot, Denis ;

Stoppa, Anne-Marie ;

Sotto, Jean-Jacques ;

Wetterwald, Marc ;

Dumontet, Charles ;

Fuzibet, Jean-Gabriel ;

Azais, Isabelle ;

Dorvaux, Veronique ;

Zandecki, Marc ;

Bataille, Regis ;

Minvielle, Stephane ;

Harousseau, Jean-Luc ;

Facon, Thierry ;

Mathiot, Claire .

BLOOD, 2007, 109 (08) :3489-3495

[4] Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival [J].

Avet-Loiseau, Herve ;

Attal, Michel ;

Campion, Loic ;

Caillot, Denis ;

Hulin, Cyrille ;

Marit, Gerald ;

Stoppa, Anne-Marie ;

Voillat, Laurent ;

Wetterwald, Marc ;

Pegourie, Brigitte ;

Voog, Eric ;

Tiab, Mourad ;

Banos, Anne ;

Jaubert, Jerome ;

Bouscary, Didier ;

Macro, Margaret ;

Kolb, Brigitte ;

Traulle, Catherine ;

Mathiot, Claire ;

Magrangeas, Florence ;

Minvielle, Stephane ;

Facon, Thierry ;

Moreau, Philippe .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) :1949-1952

[5] Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p) [J].

Avet-Loiseau, Herve ;

Leleu, Xavier ;

Roussel, Murielle ;

Moreau, Philippe ;

Guerin-Charbonnel, Catherine ;

Caillot, Denis ;

Marit, Gerald ;

Benboubker, Lotfi ;

Voillat, Laurent ;

Mathiot, Claire ;

Kolb, Brigitte ;

Macro, Margaret ;

Campion, Loic ;

Wetterwald, Marc ;

Stoppa, Anne-Marie ;

Hulin, Cyrille ;

Facon, Thierry ;

Attal, Michel ;

Minvielle, Stephane ;

Harousseau, Jean-Luc .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :4630-4634

[6] Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma [J].

Binder, M. ;

Rajkumar, S. V. ;

Ketterling, R. P. ;

Dispenzieri, A. ;

Lacy, M. Q. ;

Gertz, M. A. ;

Buadi, F. K. ;

Hayman, S. R. ;

Hwa, Y. L. ;

Zeldenrust, S. R. ;

Lust, J. A. ;

Russell, S. J. ;

Leung, N. ;

Kapoor, P. ;

Go, R. S. ;

Gonsalves, W. I. ;

Kyle, R. A. ;

Kumar, S. K. .

BLOOD CANCER JOURNAL, 2016, 6 :e401-e401

[7] A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial [J].

Boyd, K. D. ;

Ross, F. M. ;

Chiecchio, L. ;

Dagrada, G. P. ;

Konn, Z. J. ;

Tapper, W. J. ;

Walker, B. A. ;

Wardell, C. P. ;

Gregory, W. M. ;

Szubert, A. J. ;

Bell, S. E. ;

Child, J. A. ;

Jackson, G. H. ;

Davies, F. E. ;

Morgan, G. J. .

LEUKEMIA, 2012, 26 (02) :349-355

[8] The Clinical Impact and Molecular Biology of del(17p) in Multiple Myeloma Treated with Conventional or Thalidomide-Based Therapy [J].

Boyd, Kevin D. ;

Ross, Fiona M. ;

Tapper, William J. ;

Chiecchio, Laura ;

Dagrada, GianPaolo ;

Konn, Zoe J. ;

Gonzalez, David ;

Walker, Brian A. ;

Hockley, Sarah L. ;

Wardell, Christopher P. ;

Gregory, Walter M. ;

Child, J. Anthony ;

Jackson, Graham H. ;

Davies, Faith E. ;

Morgan, Gareth J. .

GENES CHROMOSOMES & CANCER, 2011, 50 (10) :765-774

[9] p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation [J].

Chang, H ;

Qi, C ;

Yi, QL ;

Reece, D ;

Stewart, AK .

BLOOD, 2005, 105 (01) :358-360

[10] Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions [J].

Chang, H ;

Sloan, S ;

Li, D ;

Stewart, AK .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (03) :280-284

← 1 2 3 4 5 6 →